Angiotensin receptor blockers and risk of prostate cancer among united states veterans

Journal of Clinical Pharmacology

Volumn 53, Issue 7, 2013, Pages 773-778

  Rao, Gowtham A ^a,b,c,g   Mann, Joshua R ^a   Bottai, Matteo ^a,d   Uemura, Hiroji ^e   Burch, James B ^a,b,c   Bennett, Charles Lee ^f   Haddock, Kathlyn Sue ^b   Hébert, James R ^a,c  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

^b WJB Dorn VA Medical Center   (United States)

^c Cancer Prevention and Control Program   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

^f University of South Carolina   (United States)

^g UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin receptor blockers; Cancer registry; Department of Veterans Affairs; Drug safety; Inverse probability of treatment weight; Propensity score; Prostate cancer; Survival analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; GLEASON SCORE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RISK ASSESSMENT; SMOKING; UNITED STATES; VETERAN;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; UNITED STATES; VETERANS;

EID: 84880275320     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.98     Document Type: Article

References (29)

1. Sipahi I, Debanne S, Rowland D, Simon D, Fang J. Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol. 2010.
2. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324?168 participants from randomised trials. Lancet Oncol. 2011;12(1):65-82.
3. Pasternak B, Svanstrom H, Callreus T, Melbye M, Hviid A. Use of angiotensin receptor blockers and the risk of cancer. Circulation. 2011;123(16):1729-1736.
4. Bhaskaran K, Douglas I, Evans S, Staa TV, Smeeth L. Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database. BMJ. 2012-04-24 00:00:00 2012; 344.
5. Collaboration TAT. Effects of telmisartan, irbesartan, valsartan, candesartan, losartan on cancers in 15 trials enrolling 138769 individuals. J Hypertens. 2011;29(4):623-635; 610.1097/HJH.1090b1013e328344a328347de.
6. Hallas J, dePont Christensen R, Andersen M, Friis S, Bjerrum L. Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study. Br J Clin Pharmacol. 2012; no-no. 7. Hoshino K, Ishiguro H, Teranishi J-I, et al. Regulation of androgen receptor expression through angiotensin II type 1 receptor in prostate cancer cells. Prostate. 2011;71(9):964-975.
7. Uemura H, Ishiguro H, Nakaigawa N, et al. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: a possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther. 2003;2(11):1139-1147.
8. Uemura H, Ishiguro H, Nagashima Y, et al. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther. 2005;4 (11):1699-1709.
9. Uemura H, Hasumi H, Kawahara T, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005;10(6):405-410.
10. Uemura H, Ishiguro H, Kubota Y. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol. 2008;15(1):19-26.
11. Hernan MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60(7):578-586.
12. VA Information Resource Center. VIReC Research User Guide: VHA Decision Support System Clinical National Data Extracts, 2nd edition. Hines, IL: U.S. Dept. of Veterans Affairs, Health; Services Research and Development Service, VA Information Resource Center, Sept. 1, 2009. http://www.virec.research.va.gov/ References/RUG/RUG-DSS-2nd-Ed-er.pdf
13. McGinnis KA, Brandt CA, Skanderson M, et al. Validating smoking data from the Veteran's Affairs Health Factors Dataset, an electronic data source. Nicotine Tob Res. 2011;13(12):1233-1239.
14. Department of Veterans Affairs (VA), VA Information Resource Center (VIReC) Web site. 2012; www.virec.research.va.gov (Accessed March 2, 2012).
15. Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19(6):766-779.
16. D'AgostinoRB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265-2281.
17. Austin PC. The performance of different propensity-score methods for estimating differences in proportions (risk differences or absolute risk reductions) in observational studies. Stat Med. 2010;29 (20):2137-2148.
18. Johnson ML, Crown W, Martin BC, Dormuth CR, Siebert U. Good research practices for comparative effectiveness research: analytic methods to improve causal inference from nonrandomized studies of treatment effects using secondary data sources: the ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report -part III. Value Health. 2009;12(8):1062-1073.
19. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-224.
20. Ager EI, Neo J, Christophi C. The renin-angiotensin system and malignancy. Carcinogenesis. 2008;29(9):1675-1684.
21. Cheng ZJ, Vapaatalo H, Mervaala E. Angiotensin II and vascular inflammation. Int Med J Exp Clin Res. 2005;11(6):RA194-RA205.
22. Rosenthal T, Gavras I. Angiotensin inhibition and malignancies: a review. J Human Hypertens. 2009;23(10):623-635.
23. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-k; B through AT1 and AT2 receptors 1. Kidney Int. 2002;61(6):1986-1995.
24. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003;163(3):879-887.
25. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst. 2008;100(17):1223-1232.
26. Miyajima A, Kosaka T, Asano T, et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res. 2002;62(15):4176-4179.
27. Wilop S, von Hobe S, Crysandt M, Esser A, Osieka R, Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-smallcell lung cancer undergoing first-line platinum-based chemotherapy. J Cancer Res Clin Oncol. 2009;135(10):1429-1435.
28. George AJ, Thomas WG, Hannan RD. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 10(11):745-759.
29. FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs-Angiotensin Receptor Blockers (ARBs). www.fda.gov (Accessed May 31, 2012).